|
Colorectal cancer treatment
Abstract
Our R&D team developed a cell-permeable Hdm2/HdmX E3 ligase inhibitor that shows in vitro activity in many cancer cell-lines (prostate carcinoma, osteosarcoma, lung carcinoma, colon carcinoma and ovarian carcinoma, among others) with p53 wt, mutated or null. This compound has shown activity in a colorectal...
|